TEMPLE, a Phase 3 multicenter, randomized, double-blind, head-to-head study, evaluated the tolerability, safety and efficacy of atogepant compared to topiramate for the preventive treatment of migraine in adult patients with a history of four or more migraine days per month
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Innovative agents highlight growth of targeted protein degradation platform and BMS' leadership in innovative cancer therapies
The companies aim to create customized AI models and agents that Novo Nordisk can use for early research and clinical development
Dilip Shanghvi to continue as the Executive Chairman of the Board
This strategic expansion marks a significant step in the company's global growth strategy
Subscribe To Our Newsletter & Stay Updated
